↓ Skip to main content

The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression

Overview of attention for article published in Molecular Cancer Therapeutics, December 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
15 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
Published in
Molecular Cancer Therapeutics, December 2014
DOI 10.1158/1535-7163.mct-13-1001
Pubmed ID
Authors

Jeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, Eun Jeong Yu, Tae Soo Kim, You Keun Shin, Xianglan Zhang, Kyu Hyun Park, Seung Woo Park, Hyun Cheol Chung, Garth Powis

Abstract

Advanced gastric cancer (GC) is one of the most aggressive gastrointestinal malignancies, ADAM (A Disintegrin and Metalloproteinase)-9 is a cell-surface membrane glycoprotein with oncogenic properties that is overexpressed in several cancers. Herein, we investigated the biological mechanism of ADAM9 in the progression, proliferation and invasion of GC. First, we detected ADAM's expression, processing and protease activity in GC cells. Protease activity was moderately correlated with ADAM9 protein expression, but was better related to a processed smaller molecular weight (84 kDa) form of ADAM9. Knockdown of ADAM9 or specifically targeted monoclonal antibody (RAV-18) suppressed cancer cell proliferation and invasion in high ADAM9 expressing cells, not in low expressing cells. RAV-18 showed in vivo antitumor activity in a GC xenograft model. Hypoxia (1% oxygen) induced ADAM9 expression and functional activity in low expressing GC cells that was inhibited by siRNA knockdown or RAV-18 antibody to levels in normoxic cells. Overall, our studies show that ADAM9 plays an important role in GC proliferation and invasion, and that while expressed in some GC cells at high levels that are responsive to functional inhibition and antitumor activity of a catalytic site directed antibody, other GC cells have low levels of expression and only when exposed to hypoxia do ADAM9 levels increase and the cells become responsive to ADAM9 antibody inhibition. Therefore, our findings suggest that ADAM9 could be an effective therapeutic target for advanced GC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 40%
Researcher 4 27%
Student > Master 2 13%
Professor 1 7%
Student > Bachelor 1 7%
Other 1 7%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 40%
Agricultural and Biological Sciences 5 33%
Medicine and Dentistry 3 20%
Unknown 1 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2022.
All research outputs
#2,995,728
of 21,673,824 outputs
Outputs from Molecular Cancer Therapeutics
#443
of 3,769 outputs
Outputs of similar age
#38,240
of 252,401 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#15
of 66 outputs
Altmetric has tracked 21,673,824 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,769 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,401 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.